-
BET Bromodomain Suppression Inhibits VEGF-induced Angiogenesis and Vascular Permeability by Blocking VEGFR2-mediated Activation of PAK1 and eNOS.
Scientific reports 20160101
-
Bridging Functional and Structural Cardiotoxicity Assays Using Human Embryonic Stem Cell-Derived Cardiomyocytes for a More Comprehensive Risk Assessment.
Toxicological sciences : an official journal of the Society of Toxicology 20151101
-
The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.
Journal of medicinal chemistry 20150108
-
The discovery of PLK4 inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as novel antiproliferative agents.
Journal of medicinal chemistry 20130808
-
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters 20130801
-
Molecular markers for novel therapeutic strategies in pancreatic endocrine tumors.
Pancreas 20130401
-
Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours.
British journal of cancer 20121009
-
Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours.
British journal of cancer 20121009
-
Rational coformer or solvent selection for pharmaceutical cocrystallization or desolvation.
Journal of pharmaceutical sciences 20121001
-
Axitinib, a new therapeutic option in renal cell carcinoma.
Drugs of today (Barcelona, Spain : 1998) 20121001
-
Case of complete response to everolimus for metastatic renal cell carcinoma.
International journal of urology : official journal of the Japanese Urological Association 20120901
-
[Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].
Magyar onkologia 20120901
-
Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer.
Investigational new drugs 20120801
-
Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma.
Japanese journal of clinical oncology 20120801
-
Concise drug review: pazopanib and axitinib.
The oncologist 20120801
-
Evaluation of the effect of food on the pharmacokinetics of axitinib in healthy volunteers.
Cancer chemotherapy and pharmacology 20120701
-
Axitinib (Inlyta) for advanced renal cell carcinoma.
The Medical letter on drugs and therapeutics 20120611
-
Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients.
Investigational new drugs 20120601
-
Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model.
Melanoma research 20120601
-
Second-line therapy after VEGF targeted therapy in metastatic renal cancer: a law of diminishing returns.
Clinical genitourinary cancer 20120601
-
[Therapeutic effect of axitinib and 5-FU in nude mice bearing human colon cancer xenograft].
Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20120601
-
Novel molecular targeted therapies for refractory thyroid cancer.
Head & neck 20120501
-
Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics.
European journal of clinical pharmacology 20120501
-
Comprehensive overview of axitinib development in solid malignancies: focus on metastatic renal cell carcinoma.
Clinical advances in hematology & oncology : H&O 20120501
-
Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A.
Cancer discovery 20120401
-
Evaluation of drugs with specific organ toxicities in organ-specific cell lines.
Toxicological sciences : an official journal of the Society of Toxicology 20120301
-
VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression.
Cancer research 20120301
-
[Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors].
Magyar onkologia 20120301
-
Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers.
Investigational new drugs 20120201
-
Axitinib modulates hypoxia-induced blood-retina barrier permeability and expression of growth factors.
Growth factors (Chur, Switzerland) 20120201
-
Pharmacokinetic evaluation of axitinib.
Expert opinion on drug metabolism & toxicology 20120201
-
Metastatic renal cell carcinoma treated sequentially with multiple VEGF receptor-targeted inhibitors--a case report.
Anticancer research 20120201
-
Drug approvals 2011: focus on companion diagnostics.
Journal of the National Cancer Institute 20120118
-
An update on targeted therapy in metastatic renal cell carcinoma.
Urologic oncology 20120101
-
VEGF-induced growth cone enhancement is diminished by inhibiting tyrosine-residue 1214 of VEGFR-2.
Cells, tissues, organs 20120101
-
Axitinib targeted cancer stemlike cells to enhance efficacy of chemotherapeutic drugs via inhibiting the drug transport function of ABCG2.
Molecular medicine (Cambridge, Mass.) 20120101
-
Peginesatide acetate, axitinib, and pertuzumab.
Journal of the American Pharmacists Association : JAPhA 20120101
-
Tilting the AXIS towards therapeutic limits in renal cancer.
Lancet (London, England) 20111203
-
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Lancet (London, England) 20111203
-
Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics.
Investigational new drugs 20111201
-
Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 20111201
-
Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma.
European journal of cancer (Oxford, England : 1990) 20111101
-
A Phase I study to evaluate the pharmacokinetics of axitinib (AG-13736) in healthy Chinese volunteers.
International journal of clinical pharmacology and therapeutics 20111101
-
Axitinib in the treatment of metastatic renal cell carcinoma.
Future oncology (London, England) 20111101
-
Comprehensive analysis of kinase inhibitor selectivity.
Nature biotechnology 20111030
-
Managing refractory metastatic renal cell carcinoma: a RECORD spinning on a tilted AXIS.
Clinical genitourinary cancer 20110901
-
Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110620
-
Anti-vascular endothelial growth factor therapy for breast cancer: can we pick the winners?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110620
-
The selective VEGFR1-3 inhibitor axitinib (AG-013736) shows antitumor activity in human neuroblastoma xenografts.
International journal of cancer 20110601
-
Rapid identification and absence of drug tests for AG-013736 in 1mg Axitinib tablets by ion mobility spectrometry and DART™ mass spectrometry.
Journal of pharmaceutical and biomedical analysis 20110601
-
The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells.
The Journal of clinical endocrinology and metabolism 20110601
-
Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 20110601
-
Axitinib for the management of metastatic renal cell carcinoma.
Drugs in R&D 20110601
-
Differential impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on axitinib brain accumulation and oral plasma pharmacokinetics.
Drug metabolism and disposition: the biological fate of chemicals 20110501
-
Antiangiogenesis enhances intratumoral drug retention.
Cancer research 20110401
-
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study.
The Lancet. Oncology 20110301
-
Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo.
Neoplasia (New York, N.Y.) 20110301
-
A thermodynamic-based approach to analyzing a highly solvating polymorphic system: the desolvation window method.
Journal of pharmaceutical sciences 20110101
-
Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.
Chemistry & biology 20101124
-
Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor.
British journal of cancer 20101109
-
Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors.
European journal of medicinal chemistry 20101101
-
Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies?
Expert review of anticancer therapy 20101001
-
Development of a targeted polymorph screening approach for a complex polymorphic and highly solvating API.
Journal of pharmaceutical sciences 20100901
-
Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: a phase I study in Japanese patients.
Cancer science 20100401
-
Molecular therapy of pancreatic cancer.
Minerva endocrinologica 20100301
-
Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers.
Cancer chemotherapy and pharmacology 20100201
-
A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology 20100201
-
Compounds in clinical Phase III and beyond.
Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20100101
-
Axitinib (AG-013736).
Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20100101
-
Liquid chromatography-tandem mass spectrometric assay for the light sensitive tyrosine kinase inhibitor axitinib in human plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20091215
-
Quality of life in patients with metastatic renal cell carcinoma: the importance of patient-reported outcomes.
Cancer treatment reviews 20091201
-
Axitinib--a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor.
Targeted oncology 20091201
-
Tyrosine kinase inhibitors and the thyroid.
Best practice & research. Clinical endocrinology & metabolism 20091201
-
Targeted molecular therapies in thyroid carcinoma.
Arquivos brasileiros de endocrinologia e metabologia 20091201
-
CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone.
British journal of cancer 20091006
-
Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090920
-
Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090810
-
Characterizing the effects of the juxtamembrane domain on vascular endothelial growth factor receptor-2 enzymatic activity, autophosphorylation, and inhibition by axitinib.
Biochemistry 20090728
-
Cellular source and amount of vascular endothelial growth factor and platelet-derived growth factor in tumors determine response to angiogenesis inhibitors.
Cancer research 20090515
-
Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma.
Cancer 20090515
-
Targeted therapies in metastatic renal cancer in 2009.
BJU international 20090501
-
Alterations in daily sequencing of axitinib and fractionated radiotherapy do not affect tumor growth inhibition or pathophysiological response.
Radiation research 20090501
-
Axitinib induces paradoxical erythropoietin synthesis in metastatic renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090120
-
Dominant effect of antiangiogenesis in combination therapy involving cyclophosphamide and axitinib.
Clinical cancer research : an official journal of the American Association for Cancer Research 20090115
-
Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
Clinical cancer research : an official journal of the American Association for Cancer Research 20081115
-
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081010
-
Novel drugs for renal cell carcinoma.
Expert opinion on investigational drugs 20081001
-
von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.
The Journal of urology 20080901
-
[Tumor vasculature as a therapeutic target in non-small cell lung cancer].
Magyar onkologia 20080901
-
Targeting angiogenesis in pancreatic cancer.
Lancet (London, England) 20080621
-
Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study.
Lancet (London, England) 20080621
-
Early clinical studies of novel therapies for thyroid cancers.
Endocrinology and metabolism clinics of North America 20080601
-
Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors.
Current opinion in investigational drugs (London, England : 2000) 20080601
-
Axitinib for renal cell carcinoma.
Expert opinion on investigational drugs 20080501
-
Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib.
Molecular cancer therapeutics 20080101
-
Health-related quality of life during treatment for renal cell carcinoma: results from a phase II study of axitinib.
Acta oncologica (Stockholm, Sweden) 20080101
-
Signaling inhibitors in metastatic renal cell carcinoma.
Cancer journal (Sudbury, Mass.) 20080101
-
Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study.
The Lancet. Oncology 20071101
-
Targeting VEGF receptors in kidney cancer.
The Lancet. Oncology 20071101
-
The addition of AG-013736 to fractionated radiation improves tumor response without functionally normalizing the tumor vasculature.
Cancer research 20071015
-
Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
Cancer 20070801
-
American Society of Clinical Oncology--43rd annual meeting. Research into therapeutics: Part 3.
IDrugs : the investigational drugs journal 20070801
-
[Oral drugs inhibiting the VEGF pathway].
Bulletin du cancer 20070701
-
AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging.
Magnetic resonance imaging 20070401
-
Phase 2 studies of sunitinib and AG013736 in patients with cytokine-refractory renal cell carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 20070115
-
Rationale and clinical results of multi-target treatments in oncology.
The International journal of biological markers 20070101
-
Rapid vascular regrowth in tumors after reversal of VEGF inhibition.
The Journal of clinical investigation 20061002
-
Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status.
BJU international 20061001
-
New treatment approaches in metastatic renal cell carcinoma.
Current opinion in urology 20060901
-
The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Leukemia research 20060701
-
Molecular targeting therapy for renal cell carcinoma.
International journal of clinical oncology 20060601
-
VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices.
Current oncology reports 20060301
-
Antiangiogenic therapy decreases integrin expression in normalized tumor blood vessels.
Cancer research 20060301
-
Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling.
American journal of physiology. Heart and circulatory physiology 20060201
-
VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature.
American journal of physiology. Heart and circulatory physiology 20060201
-
Effect of inhibition of vascular endothelial growth factor signaling on distribution of extravasated antibodies in tumors.
Cancer research 20060201
-
[Progress in therapeutic strategy for renal cell carcinoma].
Gan to kagaku ryoho. Cancer & chemotherapy 20060201
-
SU11248 and AG013736: current data and future trials in renal cell carcinoma.
Clinical genitourinary cancer 20051201
-
Heterogeneity in the angiogenic response of a BT474 human breast cancer to a novel vascular endothelial growth factor-receptor tyrosine kinase inhibitor: assessment by voxel analysis of dynamic contrast-enhanced MRI.
Journal of magnetic resonance imaging : JMRI 20051001
-
Imaging and other biomarkers in early clinical studies: one step at a time or re-engineering drug development?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050820
-
Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050820
-
Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts.
The American journal of pathology 20040701
